About Aaron M. Raphael, Esq.
Aaron Raphael is the lead attorney on the firm’s Chemistry and Life Sciences team.
Aaron has over 20 years of patent law experience, focusing his practice on counseling U.S. and foreign clients in patent procurement, due diligence investigations, and preparing patentability, validity, and infringement opinions with an emphasis on chemical, pharmaceutical, and medical diagnostic technologies. Aaron’s broader patent law experience includes strategic patent portfolio development, securing patent rights through the appellate process, and patent litigation. Aaron served on litigation teams for numerous Hatch‑Waxman litigations involving Abbreviated New Drug Applications, including paroxetine HCl (Paxil®), gemcitabine HCl (Gemzar®), and carbidopa/levodopa/entacapone (Stalevo®), and litigations involving etanercept (Enbrel®), the TRUEtrack® blood glucose meter, and metathesis catalysts (Grubbs Second Generation Catalyst). He has extensive experience in all aspects of pre-trial, trial, and post-trial proceedings.
Prior to joining J.A. LINDEMAN & CO. PLLC, Aaron was an attorney for 10 years with the law firm of Finnegan LLP in Washington, DC. While there, he focused a significant portion of his practice on patent preparation and prosecution, and opinion drafting, particularly in the chemical, pharmaceutical, and cosmetic fields. He also practiced with the law firm of O’Brien Jones PLLC, a patent law firm boutique located in McLean, VA.
- University of Michigan, B.S. in Chemistry 1996
- Emory University School of Law, J.D. 1999
District of Columbia
Registered to practice before the U.S. Patent and Trademark Office
Publications & Presentations
Aaron is a frequent speaker in the areas of patent law and pharmaceuticals, including, most recently, presenting on the following topics:
“Drug Development and Intellectual Property (Polymorphs, Co-crystals, and Salts),” Fifteenth International Workshop on Physical Characterization of Pharmaceutical Solids (June 24, 2013, Philadelphia, PA)
“Fixed Dose Combination (FDC) Drug Products, Patents, and the FDA,” Fixed Dose Combination Drug Development: Clinical, Formulation & Regulatory Strategies (June 3-6, 2013, Madison, WI)
Speech to Assa International IWPCPS-12 (Thirteenth International Workshop on Physical Characterization of Pharmaceutical Solids), June 20, 2011, Indianapolis, IN, “Drug Development and Intellectual Property (Polymorphs, Cocrystals, and Salts).”
Speech to Assa International IWPCPS-11 (Eleventh International Workshop on Physical Characterization of Pharmaceutical Solids), June 17, 2009, Stamford, CT, “Novelty and Inherent Anticipation as Criteria for the Patentability of Crystalline Forms.”
Speech at Biotechnology Industrial Organization (BIO) 2005 on the subject of authorized generics and data exclusivity under the Hatch-Waxman Act.
Co-Author, “Drafting Patent Validity & Infringement Opinions In a Sea of Jurisprudential Chaos” (Patent Resources Group 2005).